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2681Despite a plethora of observational data supporting
a relationship between vitamin D and cardiovas-
cular health via pathways involving BP and large
artery stiffness, evidence from our high-quality
clinical trial and other existing trials do not support
the use of vitamin D supplementation as an inter-
vention to improve these endpoints. Previously
documented associations between vitamin D, aPWV,
and BP are likely to be epiphenomena rather
than causative, and vitamin D supplementation for
these aspects of cardiovascular health cannot be
recommended.Panagiota Veloudi, MRes
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NephropathyWe congratulate Bohm et al. (1) for their interesting
study regarding the effects of warfarin or dabigatran
etexilate (DE) on renal function in the patientswith atrial ﬁbrillation (AF) receiving oral anti-
coagulation, showing a decline in renal function
that was greater in those taking warfarin compared
with DE, which was ampliﬁed by diabetes and pre-
vious vitamin K antagonist use. The authors pro-
pose this adverse renal outcome may be due to
inhibition by warfarin of vitamin K–dependent ma-
trix gamma-carboxyglutamic acid (Gla/MPG) and
resulting in renal vascular calciﬁcation and arterial
damage.
Recent data showed that excessive anticoagulation
with warfarin can result in acute kidney injury (AKI)
by causing glomerular hemorrhage and renal tubular
obstruction by red blood cell (RBC) casts in some
patients, especially in those with chronic kidney
disease (CKD), which was described as warfarin-
related nephropathy (WRN) (2). Brodsky et al. (3)
was the ﬁrst to describe this entity through kidney
biopsy in a subset of patients with warfarin overdose,
hematuria, and AKI, and each biopsy specimen
demonstrated evidence of acute tubular injury,
glomerular hemorrhage, and renal tubular obstruc-
tion by RBC casts. Actually, oxidative stress damage
to tubules by an RBC cast, even though the RBC cast
did not obstruct the tubule, could lead to WRN. Other
important mechanisms, including atheroembolism,
interstitial nephritis, apoptosis of glomerular endo-
thelial cells, and direct effects of warfarin on the
glomerulus, may also contribute to the development
of WRN.
A recent case report (4) also described an
anticoagulant-related AKI in a patient who was re-
ceiving the thrombin inhibitor dabigatran. Further-
more, Ryan et al. (5) investigate the effects of
dabigatran on kidney function in an animal model of
CKD, demonstrating that dabigatran resulted in
a dose-dependent increase in serum creatinine and
hematuria in both control and 5/6 nephrectomy rats.
Morphologically, the ﬁndings in 5/6 nephrectomy
rats treated with dabigatran were similar to those
found in animals with WRN, involving RBC tubular
casts and acute tubular injury. Unexpectedly, in
comparison with WRN, in which kidney injury was
seen only in 5/6 nephrectomy rats, the effects of
dabigatran were highlighted in control rats as
well. These ﬁndings suggest that the risk to the kid-
ney by dabigatran may be greater than that by
warfarin in patients with normal renal function,
which should be taken into account in clinical
practice, indicating that regular monitoring of
kidney function may be necessary in patients re-
ceiving oral anticoagulation therapy including
warfarin or dabigatran.
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2228–34.REPLY: Anticoagulant-Related NephropathyWe thank Dr. Yang and colleagues for their interest
in our analysis of changes in renal function in
the RE-LY (Randomized Evaluation of Long Term
Anticoagulant Therapy) study over time in patients
with atrial ﬁbrillation treated with dabigatran or
warfarin (1).
We agree that kidney function must be monitored
closely in patients receiving oral anticoagulants. The
differential effects of dabigatran and warfarin that Dr.
Yang and colleagues reference are from animal models
that, although interesting, may not represent patients.
The rat study comparing those having ﬁve-sixth of
their kidney removed with controls, with both
receiving high doses of dabigatran, led to an increase in
serum creatinine and hematuria (2). This is expected
with supratherapeutic dabigatran doses and severe
renal failure. In humans, severe renal function is a
contraindication for dabigatran. To date, there is noevidence of dabigatran-induced renal injury in animals
or humans. In our subanalysis from the RE-LY study
(1), the decline in renal function corresponds well to
the physiological decline seen in elderly populations.
We believe, therefore, that there is no evidence to
support renal toxicity in patients prescribed dabiga-
tran in approved doses in patients with a creatinine
clearance >15 ml/min. We do believe that monitoring
renal function is critical to avoid prescribing dabiga-
tran at inappropriate doses or at all if renal function
does decline, which can occur for multiple well-known
reasons independent of dabigatran administration.*Michael Böhm, MD
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Acute Decompensated
Heart FailureGrodin et al. (1) showed that low admission chloride
levels are associated with worse outcomes in patients
